

# Richard Taubert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2045591/publications.pdf>

Version: 2024-02-01

43  
papers

1,217  
citations

430754

18  
h-index

395590

33  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1223  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	3.6	16
2	Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 519-531.	2.6	19
3	mRNA therapeutics for liver diseases: HNF4A mRNA delivery via lipid nanoparticles attenuates liver fibrosis in preclinical models.. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	0
4	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	1.8	21
5	Pulmonary Arterial Hypertension and Consecutive Right Heart Failure Lead to Liver Fibrosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 862330.	1.1	6
6	Liver Transplantation After Organ Donation Due to Hydrogen Sulfide Intoxication: Report of the First Case. <i>Transplantation</i> , 2022, 106, e247-e248.	0.5	0
7	Evaluation of a gene expression biomarker to identify operationally tolerant liver transplant recipients: the LITMUS trial. <i>Clinical and Experimental Immunology</i> , 2022, 207, 123-139.	1.1	4
8	Elevated fractional donorâ€derived cellâ€free DNA during subclinical graft injury after liver transplantation. <i>Liver Transplantation</i> , 2022, 28, 1911-1919.	1.3	12
9	CKâ€18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. <i>Liver International</i> , 2021, 41, 123-127.	1.9	3
10	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. <i>Biomedicines</i> , 2021, 9, 353.	1.4	18
11	Liver-first strategy for a combined lung and liver transplant in patients with cystic fibrosis. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 822-830.	0.6	2
12	Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review. <i>European Journal of Medical Genetics</i> , 2021, 64, 104214.	0.7	10
13	Distinct Immune Imprints of Postâ€Liver Transplantation Hepatitis C Persist Despite Viral Clearance. <i>Liver Transplantation</i> , 2021, 27, 887-899.	1.3	4
14	SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 1506-1509.	1.8	2
15	Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. <i>Journal of Hepatology</i> , 2021, 75, 1420-1433.	1.8	70
16	Non-invasive alloimmune risk stratification of long-term liver transplant recipients. <i>Journal of Hepatology</i> , 2021, 75, 1409-1419.	1.8	31
17	Adjuvant Therapy with Budesonide Post-Kasai Reduces the Need for Liver Transplantation in Biliary Atresia. <i>Journal of Clinical Medicine</i> , 2021, 10, 5758.	1.0	3
18	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1609-1617.e4.	2.4	25

#	ARTICLE	IF	CITATIONS
19	DSA Are Associated With More Graft Injury, More Fibrosis, and Upregulation of Rejection-associated Transcripts in Subclinical Rejection. <i>Transplantation</i> , 2020, 104, 551-561.	0.5	32
20	Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. <i>Scientific Reports</i> , 2020, 10, 14242.	1.6	29
21	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , 2020, 40, 2164-2171.	1.9	16
22	Therapeutic plasma exchange in acute on chronic liver failure. <i>Journal of Clinical Apheresis</i> , 2020, 35, 316-327.	0.7	10
23	The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality. <i>Liver International</i> , 2020, 40, 149-153.	1.9	22
24	Effects of adenovirus-induced hepatocyte damage on chronic bile duct inflammation in a sclerosing cholangitis mouse model. <i>Liver International</i> , 2019, 39, 2330-2340.	1.9	2
25	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2068-2075.e2.	2.4	55
26	Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. <i>JHEP Reports</i> , 2019, 1, 437-445.	2.6	48
27	Tipping the Balance. <i>Transplantation</i> , 2019, 103, 4-6.	0.5	0
28	Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. <i>Scientific Reports</i> , 2018, 8, 419.	1.6	15
29	Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 186-189.	2.4	17
30	Editorial: “œreal world data” of AIH – time to connect!. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1315-1316.	1.9	1
31	Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. <i>Scientific Reports</i> , 2018, 8, 17452.	1.6	22
32	Novel therapeutic targets in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2018, 95, 34-46.	3.0	28
33	Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice. <i>Journal of Autoimmunity</i> , 2018, 91, 83-96.	3.0	14
34	The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development. <i>Journal of Autoimmunity</i> , 2017, 78, 39-45.	3.0	24
35	Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. <i>PLoS ONE</i> , 2017, 12, e0179074.	1.1	33
36	Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. <i>PLoS ONE</i> , 2017, 12, e0181107.	1.1	33

#	ARTICLE	IF	CITATIONS
37	Preferential accumulation of T helper cells but not cytotoxic T cells characterizes benign subclinical rejection of human liver allografts. <i>Liver Transplantation</i> , 2016, 22, 943-955.	1.3	25
38	Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigens. <i>Hepatology</i> , 2015, 61, 1295-1305.	3.6	32
39	Increased HEV Seroprevalence in Patients with Autoimmune Hepatitis. <i>PLoS ONE</i> , 2014, 9, e85330.	1.1	61
40	HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans. <i>Science Translational Medicine</i> , 2014, 6, 242ra81.	5.8	74
41	Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. <i>Journal of Hepatology</i> , 2014, 61, 1106-1114.	1.8	119
42	Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4 <sup>+</sup> T cells. <i>Hepatology</i> , 2013, 58, 718-728.	3.6	74
43	Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. <i>Journal of Clinical Investigation</i> , 2012, 122, 368-382.	3.9	183